Brembo H1 2020 Results




Compared to H1 2019:​

Revenues​ amounted to €951.1 million (-28.2%)​

EBITDA margin at 15.1% to €143.3 million​

EBIT margin at 4.1% to €38.8 million​

Net investments for the period​ 

amounted to €73.4 million​

Net financial debt​ at €597.5 million (€407.2 million prior to the application of IFRS 16), up €147.1 million compared to 31 March 2020



Brembo Chairman Alberto Bombassei stated: 

“The results for the first half of 2020 approved by the Board of Directors today underscore how Brembo showed considerable resilience in such a challenging environment, protecting its margin levels and financial solidity. The Company believes it is well-positioned for the market evolution, thanks to its commitment towards innovation, digitalisation and environmental protection, despite the continuing situation of uncertainty of the automotive industry, further exacerbated by the crisis that has impacted the global economy. We look to the future with confidence, relying on our solid fundamentals and an ambitious development programme focused on the long term, which will allow us to resume our growth.”


H1 2020 Results​

Brembo’s Board of Directors chaired by Alberto Bombassei examined and approved the Group’s half-year results at 30 June 2020. 

In the first half of 2020, net consolidated revenues amounted to €951.1 million, down 28.2% compared to the first half of the previous year. As expected, H1 2020 results were severely impacted by the gradual spread at global level of the COVID-19 pandemic, which particularly penalised the second quarter of the year. 

Within this scenario, in H1 2020, Brembo’s sales for the car segment declined by 27.7%, motorbike applications by 34.0%, applications for commercial vehicles by 25.6% and those for racing vehicles by 27.5% compared to the same period of 2019. 

At geographical level, the performance of the various markets reflected the COVID-19 pandemic’s different timing of spread and the gradual adoption of containment measures by governments. Sales dropped by 25.6% in Italy, by 32.5% in Germany, by 22.5% in France and by 40.5% in the United Kingdom. In Asia, sales in India and Japan decreased by 43.4% and 12.1%, respectively, whereas in China sales declined by just 2.4%, thanks to a good recovery of the market, with Q2 sales up 23.2%. 

The North American market (USA, Mexico and Canada) shrank by 34.8% and the South American market (Brazil and Argentina) by 43.9%. 

In H1 2020, the cost of sales and other net operating costs amounted to €607.6 million, with a 63.9% ratio to sales, up in percentage terms compared to the same period of the previous year (H1 2019: €823.8 million; 62.2% of sales). 

Personnel expenses amounted to €202.1 million, with a 21.2% ratio to sales, increasing compared to the same period of the previous year (17.8% of sales). At 30 June 2020, workforce numbered 10,731, compared to 10,868 at 31 December 2019 and 10,579 at 30 June 2019. 

EBITDA for H1 2020 amounted to €143.3 million (EBITDA margin: 15.1%), compared to €270.6 million for the first half of 2019 (EBITDA margin: 20.4%). EBIT was €38.8 million (EBIT margin: 4.1%) compared to €174.5 million (EBIT margin: 13.2%) for H1 2019. 

Net interest expense for the period amounted to €14.2 million (€6.7 million in H1 2019); this item includes net exchange losses for €7.6 million (net exchange gains of €1.0 million in H1 2019) and interest expense amounting to €6.6 million (€7.7 million in H1 2019). 

Pre-tax profit was €24.7 million compared to €167.9 million for the first half of 2019. Based on the tax rates applicable under current tax regulations in force in each country, estimated taxes amounted to €4.5 million (€37.0 million in H1 2019), with a tax rate of 18.2% compared to 22.0% for the same period of the previous year. 

The reporting period ended with a net profit of €20.0 million, accounting for 2.1% of sales. 

Net financial debt at 30 June 2020 amounted to €597.5 million, increasing by €147.1 million compared to 31 March 2020. Without the impact of IFRS 16, net financial debt would have been €407.2 million, up €152.5 million compared to 31 March 2020.


Stake in Pirelli S.p.A.​

Adopting a long-term, non-speculative approach, Brembo has autonomously decided to invest in Pirelli S.p.A., a company that thanks to its history, brand, leadership and drive for innovation represents, just like Brembo, an example of Italian excellence within its market of reference. Brembo, both directly and through its parent company Nuova FourB, completed the acquisition process and now holds a 4.99% stake in Pirelli S.p.A.​


Measures to contain the impacts generated by the COVID-19 emergency​ 

The World Health Organization announced the spread of the disease COVID-19 from China, particularly from the Wuhan district, in early January 2020; it then declared COVID-19 a global health emergency of international concern on 30 January. In February the virus spread to Europe and America, resulting to the global lockdown in March and April. 

Brembo has been following developments relating to the spread of the COVID-19 very closely since its outbreak, establishing a dedicated task force and promptly adopting all necessary measures to monitor, prevent and contain the pandemic at all of its locations worldwide. 

In view of the production sites’ reopening, after lockdown periods whose length varied from one country to the next, the Group has defined significant measures aimed at combating the virus and protecting the health of employees and contractors such as: rearrangement of production layouts, sanitisation of the premises, purchases of personal protective equipment, temperature measurement with heat scans, circulation of hygiene rules and social distancing, and extended remote working. 

After an initial donation of €150,000 in support of treatment facilities at Bergamo's Pope John XXIII Hospital, Brembo decided to support research into combating COVID-19 by donating €1 million to three première Bergamo institutions: Pope John XIII Hospital, the Bergamo Hospital Research Foundation (FROM) and the Mario Negri Institute, which are committed to the area most severely affected by the pandemic, through a combination of clinical and pharmacological research. 

With reference to financial aspects, in adopting the prudential approach proposed by the Board of Directors in its extraordinary meeting on 20 March 2020, the Shareholders’ Meeting held on 23 April resolved not to distribute dividends drawing on the 2019 profit. This decision aims at supporting the Group’s financial solidity and limiting future economic and financial impacts. 

To face this difficult time for the market, between April and May 2020, the Group's financial structure was further reinforced by entering into new medium/long-term loans for a total amount of €425 million, in addition to available short-term credit lines for €384 million, which have not been used. These new loans enabled the Group to extend the average life of its debt, at costs in line with current levels. 

In order to contain the cost of idle personnel, redundancy schemes and other forms of public support were activated to protect workers in all countries. Moreover, plans were drawn up to contain costs, investments and working capital.​


Foreseeable Evolution​ 

The strategies adopted by the Company and the measures taken in response to the severe COVID-19 pandemic described above allowed it to weather these difficult months while protecting the Group’s margin levels and its financial solidity. Hoping that the worst stage has passed, the Group looks to the future with the confidence that its solid fundamentals will consolidate the sustainability of the business.​​